tiems, kas nesupranta angliskai ir/ar tingi skaityti, reziumuoju: zlugo eilinis bandymas sukurti kontraceptika vyrams; artimiausioje ateityje ir toliau tabletes teks ryti merginoms
LONDON – Bayer Schering Pharma, a goliath in the contraceptive market, is throwing in the towel on the so-called "pill for men."
The company is officially staying tightlipped about its reasons for abandoning development of a male contraceptive, but it likely wants to focus on more profitable areas of business, and it has also probably been unable to find a suitable treatment for widespread use.
The treatment, which isn’t actually a pill but a series of injections of male and female hormones along with an implant, had been developed with Organon Pharmaceuticals USA. But the Roseland, New Jersey-based partner, which is a subsidiary of the Dutch chemicals firm Akzo Nobel (nasdaq: AKZOY – news – people ), dropped out of the project in September.
The companies at that time said they had been unable to find a treatment for everyday use. Phil Smits, the head of gynecology and andrology at Schering had said the research program had been "long and demanding," but that Schering would continue to research the treatment on its own.
A spokeswomen for Bayer (nyse: BAY – news – people ) said Bayer Schering Pharma would reveal details about its decision to terminate the research on June 19, when the company would present its pipeline strategy following the integration of its $20 billion acquisition of Schering, a maker of birth-control pills and biotech drugs with sales of $6 billion last year. (See "Avaricious In Germany")
"Before that we don’t want to disclose any details so as not cause any undue speculation," the spokeswoman said. "But obviously if we are ending research it means we don’t put the resources into that as we have done before."
Bayer Schering Pharma is planning to focus on four areas: oncology, women’s health, cardiology and diagnostics, according to a report in German newspaper Tagesspiegel.